Trevi Therapeutics, Inc. (TRVI)
Nasdaq · Healthcare · Biotechnology
$13.72−1.37%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.0B
- 52-week range
- $9.28 – $20.22
- 52-week change
- +39.80%
- EPS (trailing)
- −$0.35
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$42.8M
- Diluted EPS
- −$0.32
- Free cash flow
- −$42.1M
From the company’s annual report on SEC EDGAR.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Headquarters: New Haven, United States · 34 employees · trevitherapeutics.com